中国中医科学院西苑医院
纸质出版:2018
移动端阅览
[1]朱千赜,胡晓梅,王洪志,王德秀,杨秀鹏,许勇钢,郭小青,麻柔.青黄散胶囊为主治疗骨髓增生异常综合征150例回顾性分析[J].中医杂志,2018,59(04):303-306.
ZHU Qianze, HU Xiaomei, WANG Hongzhi, et al. Qinghuang Powder Capsule ( 青黄散胶囊) as the Main Method in Treating 150 Cases of Myelodysplastic Syndrome,a Retrospective Analysis[J]. Journal of Traditional Chinese Medicine2018, 59(4): 303-306.
[1]朱千赜,胡晓梅,王洪志,王德秀,杨秀鹏,许勇钢,郭小青,麻柔.青黄散胶囊为主治疗骨髓增生异常综合征150例回顾性分析[J].中医杂志,2018,59(04):303-306. DOI: 10.13288/j.11-2166/r.2018.04.009.
ZHU Qianze, HU Xiaomei, WANG Hongzhi, et al. Qinghuang Powder Capsule ( 青黄散胶囊) as the Main Method in Treating 150 Cases of Myelodysplastic Syndrome,a Retrospective Analysis[J]. Journal of Traditional Chinese Medicine2018, 59(4): 303-306. DOI: 10.13288/j.11-2166/r.2018.04.009.
目的回顾性分析以青黄散胶囊为主治疗骨髓增生异常综合征患者的临床疗效。方法纳入骨髓增生异常综合征患者150例
其服用青黄散胶囊至少24个月(每日0.3 g
晚饭后服用)
同时联合雄激素和补肾健脾中药汤剂口服。观察患者治疗3、6、9、16、24、30、40个月的外周血血红蛋白(HGB)、血小板计数(PLT)、中性粒细胞计数(ANC)
评价各指标获得血液学进步的例数及时间
并对不同危险度、骨髓增生程度患者各指标获得血液学进步时间进行比较;记录治疗40个月患者贫血改善情况和红细胞输注情况。结果 150例患者完成了24个月治疗
其中完成了30个月治疗者136例
完成了40个月治疗者118例。150例患者治疗前HGB、PLT、ANC低于正常的例数分别为115例、129例、56例。治疗40个月期间HGB异常患者较PLT及ANC异常患者血液学进步率高
血液学进步时间短(P<0.05)
而PLT与ANC异常患者比较差异无统计学意义(P>0.05)。不同危险度患者各指标获得血液学进步时间差异无统计学意义(P>0.05)。低增生性患者PLT获得血液学进步时间明显长于非低增生性患者(P<0.05)。经Person相关性检验
随着治疗时间延长红细胞输注依赖的患者显著减少(r=-0.92
P<0.05)。结论青黄散胶囊为主治疗骨髓增生异常综合征可明显改善患者外周血HGB、PLT、ANC
且对HGB的改善更为明显
起效时间短
作用时间长。
Objective To retrospectively analyze clinical curative effect of Qinghuang Powder Capsule as the main method in treating patients with myelodysplastic syndrome. Methods One hundred and fifty cases of myelodysplastic syndrome were collected. All patients have used Qinghuang Powder Capsule for at least 24 months( 0. 3 g daily
taken after dinner)
at the same time combining with orally taking androgen and decoction for tonifying kidney and spleen. Peripheral blood hemoglobin( HGB)
platelet count( PLT)
and neutrophil count( ANC) of patients after being treated for 3
6
9
16
24
30 and 40 months were observed. The case number and time of each index acquiring hematology progress were evaluated. The time it took for each index of patients with different risk factors and bone marrow hyperplasia degree to acquire hematology progress were compared; and the improvement of anemia and erythrocyte infusion condition in the 40 th month of treatment was recorded. Results There were 150 patients who completed the 24-month treatment
of which 136 completing 30-month treatment
and 118 completing 40-month treatment. In 150 cases
the number of patients whose HGB
PLT and ANC before treatment lower than normal was 115
129 and 56 cases respectively. During 40-month treatment
hematology progress rate of patients with abnormal HGB were higher and hematology progress time was shorter than those with abnormal PLT and ANC( P < 0. 05)
while the difference between patients with abnormal PLT and ANC was not statistically significant( P > 0. 05). There was no significant difference in time took for each index improvementbetween patients with different risk to acquire hematological progress( P > 0. 05). The time took for PLT improvement of patients with low proliferative to acquire hematological progress was significantly longer than that of non-hypoproliferative patients( P < 0. 05). Through Person correlation test
the patients with erythrocyte infusion dependence were significantly reduced as treatment time stretched( r =-0. 92
P < 0. 05). Conclusion Qinghuang Powder Capsule as the main method treating myelodysplastic syndrome could obviously improve HGB
PLT
ANC in peripheral blood
and improved HGB more significantly. Its onset time was short and could work for a long time.
0
浏览量
377
下载量
3
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010102007558号